The report “Antibody Technologies
and Attrition Rates – an industry analysis 2013” is based on the identification
of the antibody generation technologies of 504 naked antibodies in clinical or
market stages. Information was retrieved from scientific and corporate
publications as well as from patent and legal literature. The report provides
descriptive statistics of the 504 naked antibodies and their status during the
study period of January 1, 2013 to February 28, 2013. The antibodies are
categorized as active during the study period or discontinued during or before
the study period. Attrition rates were calculated across a number of
variables.
To Read the Complete Report with TOC
Visit: http://www.marketresearchreports.biz/analysis/166811
Descriptive statistics of the 504
naked antibodies include the following variables:
- Unique antibody identifiers (drug codes; generic name; brand name)
- Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
- In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
- In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
- Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
- Antibody status (active/discontinued)
- Year of failure
- Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
- Target
- Immunoglobulin class and IgG isotype
- Highest phase
- Therapeutic area of lead indication
- Companies (developer, licensor/originator)
An Antibody Data Sheet was prepared
for each unique antibody containing the retrieved information and the source of
information in the form of a scientific reference or a hyperlink leading to the
website from which the information was obtained. The analysis essentially
evaluated the question whether there are differences in clinical attrition
rates between in vitro and in vivo antibody generation technologies as well as
within the different in vitro and in antibody generation technologies. Attrition
rate was defined as the percentage of failed antibodies of all active and
inactive antibodies.
To
Buy the Copy Of This Report Visit:
http://www.marketresearchreports.biz/analysis-details/antibody-technologies-and-attrition-rates-an-industry-analysis-2013
Benefits from the data and the
analysis:
- Understand the historical and present state of the art use of antibody technologies;
- Learn the success rate of each antibody generation technology;
- Understand the reasons for failure of antibodies in clinical development;
- Appreciate the relative value of generic and of IP protected antibody technologies;
- Know which antibody technologies are using your competitors;
- Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.
- Learn the influence of the target for the success rate of the selected antibody technology.
Latest Report:
Antibody Technologies
and Attrition Rates - an industry analysis 2013: http://www.marketresearchreports.biz/analysis/166811
The report “Antibody Technologies
and Attrition Rates – an industry analysis 2013” is based on the identification
of the antibody generation technologies of 504 naked antibodies in clinical or
market stages. Information was retrieved from scientific and corporate
publications as well as from patent and legal literature. The report provides
descriptive statistics of the 504 naked antibodies and their status during the
study period of January 1, 2013 to February 28, 2013. The antibodies are
categorized as active during the study period or discontinued during or before
the study period. Attrition rates were calculated across a number of variables.
Descriptive statistics of the 504
naked antibodies include the following variables:
- Unique antibody identifiers (drug codes; generic name; brand name)
- Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
- In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
- In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
- Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
- Antibody status (active/discontinued)
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Blog: http://indiamarketreports.blogspot.com/
No comments:
Post a Comment